

Yutrepia[™] (treprostinil) – New drug approval

- On May 23, 2025, <u>Liquidia Corporation announced</u> the <u>FDA approval</u> of <u>Yutrepia (treprostinil)</u> inhalation powder, for the <u>treatment of</u>:
 - Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability
 - Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.
- Treprostinil is currently available via several other formulations, including United Therapeutics' inhalation powder (<u>Tyvaso DPI®</u>).
- Warnings and precautions for Yutrepia include risk of symptomatic hypotension, risk of bleeding, effect of other drugs on treprostinil, and bronchospasm.
- The most common adverse reactions (≥ 10%) with Yutrepia use were cough, headache, throat irritation, and dizziness.
- Refer to the Yutrepia label for complete dosing and administration recommendations.
- United Therapeutics filed a complaint in a U.S. District Court against Liquidia on May 9, 2025, alleging patent infringement. United Therapeutics has filed a motion for temporary restraining order and preliminary injunction to block Liquidia from commercially launching Yutrepia. The motion remains pending with the Court.
- Yutrepia will be available as an inhalation powder contained in capsules (26.5 mcg, 53 mcg, 79.5 mcg, and 106 mcg).



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.